Full-Time
Senior Clinical and Sales Specialist
Johnson & Johnson
10,001+ employees
Global healthcare company offering pharma, devices.
No salary listed
Brisbane QLD, Australia
In Person
Field-based role in Eight Mile Plains, Queensland; requires rights to work in Australia.
Bachelor's
 Sales & Account Management (1) |
|---|
Get referred to Johnson & Johnson
See people who can refer or advise you
- Account Management
- Analytical Reasoning
- Business Behavior
- Collaboration
- Cultural Competence
- Customer Analytics
- Customer Centricity
- Healthcare Trends
- Learning Agility
- Market Knowledge
- Market Research
- Oracle Customer Data Management (CDM)
- Problem Solving
- Sales
- Solutions Selling
- Sustainable Procurement
- Vendor Selection
- All applicants must have rights to work in Australia.
- Preferred minimum education: Degree in Health Science or Biomedical Engineering
- Preferred industry experience: EP Cardiac technician, IBHRE completed or current with line manager within 12 months.
- Minimum 3 years of experience in a Clinical role
- In-depth understanding of Electrophysiology and catheters.
- Signed off and expert in all arrhythmias, hardware and software
- Strong leadership with an ability to work autonomously
- Proven track record of new technology adoption
- Pass mark of >85% recert/ASTM
- Provide expert procedural support on advanced electrophysiology cases, especially complex arrhythmias
- Lead training sessions and mentor in-field teams, ensuring everyone is at the top of their game
- Collaborate with physicians, nurses, and technologists to optimize patient outcomes
- Troubleshoot and resolve product issues quickly to keep procedures running smoothly
- Drive product adoption by proactively showcasing innovations and benefits to healthcare professionals
- Assist with product recalls, complaints, and feedback to enhance future development
- Support sales efforts by identifying clinical opportunities and demonstrating product value
- Represent Johnson & Johnson at industry events and conferences, sharing your expertise
- Degree in Health Science or Biomedical Engineering
- EP Cardiac technician, IBHRE completed or current with line manager within 12 months
- None, since after filtering the text for non-trivial items, the job posting does not list any "desirable" or "preferred" qualifications.
Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.
Company Size
10,001+
Company Stage
IPO
Headquarters
New Brunswick, New Jersey
Founded
1886
Get referred to Johnson & Johnson
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 sales rose 6.6% to $25.3 billion, and guidance lifted to $101.1 billion.
- Tremfya grew 72.5% in Q2 2026, offsetting Stelara's patent loss.
- OTTAVA's July 2026 launch plus ongoing hernia trials create a long runway for adoption.
What critics are saying
- Stelara biosimilars and Medicare price cuts pressure immunology revenue throughout 2026.
- Talc settlement still needs 95% claimant approval, and future lawsuits remain outside coverage.
- Abiomed Impella weakness and surgeon skepticism threaten MedTech growth if Q3 volumes stay soft.
What makes Johnson & Johnson unique
- J&J spans pharmaceuticals, MedTech, and consumer health, reducing single-product dependence.
- OTTAVA gained FDA authorization on July 22, 2026, opening a new soft-tissue robotics category.
- AAA credit status and 64-year dividend streak signal exceptional capital discipline.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Paid Holidays
Remote Work Options
Performance Bonus
Growth & Insights and Company News
6 month growth
↓ -4%1 year growth
↓ -4%2 year growth
↓ -2%Johnson & Johnson leads a portfolio of four dividend-growth stocks that together generate $2,304 in annual passive income from a $100,000 investment split equally. The group delivers a 2.30% blended yield. SBA Communications tops the quartet with a 2.58% yield. Johnson & Johnson brings a 64-year dividend streak and AAA credit rating, making it a core income holding. Equinix, which converted to a REIT in 2015, runs the world's largest neutral interconnection footprint. The company generated $2.63 billion in Q2 revenue and has grown its quarterly payout from $2.66 in 2020 to $5.16 today. Institutions own 99.6% of the float. All four stocks trade on major exchanges with tight spreads, offering liquidity advantages over alternatives like rental real estate or mortgage REITs.
Johnson & Johnson returned $85 billion to shareholders over the past five years through $60 billion in dividends and $25 billion in share buybacks, equivalent to 13.8% of its current market capitalisation. The healthcare giant generated $97.93 billion in revenue over the last twelve months with a 27% operating margin. Despite this substantial cash return, JNJ shareholders saw a total return of 70% over five years, underperforming the S&P 500's 83% return. The company's Innovative Medicine division showed strong performance, with double-digit growth excluding STELARA and successful launches like ICOTYDE. However, the MedTech segment struggled, particularly in cardiovascular, where the Abiomed heart pump business saw sales decline 2%. The performance gap between divisions raises questions about whether returning cash signals disciplined capital allocation or a shortage of high-return growth opportunities.
Johnson & Johnson reported strong Q2 2026 results with sales rising nearly 7% to $25.31 billion, beating estimates of $25.05 billion. Adjusted earnings per share reached $2.90, surpassing the expected $2.85. The company raised its full-year guidance and remains on track to exceed $100 billion in annual revenue for the first time in its 140-year history. Its pharmaceutical division generated $16.38 billion in quarterly sales. Despite a 55% drop in Stelara revenue to $740 million due to patent loss, newer drugs compensated for the decline. Tremfya sales surged 72.5% to $2 billion, well above the $1.74 billion estimate. Meanwhile, Danaher delivered encouraging Q2 results driven by its Life Sciences business, with bioprocessing orders growing mid-teens despite timing-related revenue fluctuations.
Johnson & Johnson has agreed to pay $5.5 billion to settle approximately 76,000 lawsuits alleging its talc-based baby powder caused ovarian cancer. The settlement requires acceptance by at least 95% of claimants to take effect. The company expects to make an initial payment of no more than $3 billion in 2027, with additional payments due from 2028. Legal representatives suggest the total payout could reach $7 billion or more. The deal is designed to deliver payment to all claimants within 18 months and covers only current claims, leaving future lawsuits outside its scope. J&J maintains the claims lack merit but said the settlement allows it to move forward. The agreement follows three years of halted proceedings whilst J&J pursued unsuccessful bankruptcy strategies through a subsidiary. The company withdrew its talc-based baby powder from US shelves in 2020 and worldwide in 2023.
Johnson & Johnson's MedTech segment delivered mixed second-quarter 2026 results. Sales rose 4.5% to $8.93 billion but missed the consensus estimate of $8.96 billion. The shortfall stemmed from weaker cardiovascular performance, particularly in Abiomed, where sales declined 2% due to slow procedural volumes for the Impella heart pump. Physician uncertainty following a UK study questioning Impella's benefit in certain high-risk procedures contributed to reduced usage. Despite cardiovascular weakness, J&J's Surgery, Vision, and Orthopedics businesses accelerated above expectations, growing 3.9%, 6.0%, and 4.9% respectively. Shockwave revenues rose 14.6% to $335 million. J&J characterised the Abiomed issue as temporary and noted stable overall procedure volumes across its MedTech business, with no meaningful impact from expired Affordable Care Act subsidies.